New funding will be used to support Jupiter Endovascular in its upcoming pivotal trial for Pulmonary Embolism. It will also aid development of additional clinical applications of the Endoportal ControlTM technology. The company tells us it has exited stealth mode with a $21 million new round of financing.
Background
Medtech startup, Jupiter Endovascular, Inc. is aiming to bring the precision and control of direct surgical access to catheter-based interventions. Jupiter is developing a new class of endovascular procedures using Endoportal ControlTM. The procedure uses an endoportal device that navigates flexibly through the vasculature via percutaneous access. Once in position, the clinician can fix the endoportal device into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. To learn more about Jupiter Endovascular, visit www.jupiterendo.com.
Jupiter Endovascular and Sonder Capital
Sonder Capital was a key participant in the round that included participation from multiple strategic investors. Founded in 2019, Sonder’s team comprises veteran investors, innovators, founder-operators, and company builders. In a news release, managing partner Kate Garrett speaks about the technology. “For decades, the field of catheter-based therapies has been limited by the technological constraints of catheters that lose stability and control within the anatomy. Jupiter Endovascular has developed a revolutionary approach with the potential to overcome these constraints. It provides clinicians the precision and control of a surgical approach. All of this while maintaining the minimally invasive profile of an endovascular procedure. This novel approach may address a significant unmet clinical need in patients with disease residing in complex cardiovascular anatomies, such as the pulmonary arteries.”
The company has appointed Carl J. St. Bernard as Jupiter Endovascular’s Chief Executive Officer. St. Bernard, an industry veteran with a wealth of medical technology leadership experience, joins Jupiter from Alta Biomaterials, where he held the role of President and CEO. He has over 30 years of experience in the life sciences arena and has held senior executive positions at CeloNova BioSciences, Tryton Medical, Johnson & Johnson Vision, LifeCell, Cordis, and GE Healthcare. He is also an AdvaMed board director.
“We are excited to welcome Carl St. Bernard as the CEO of Jupiter Endovascular,” said Jay Watkins. Jay is Co-Chair and Partner at Sonder Capital. “Carl brings a wealth of experience and proven track record of success in bringing novel technologies and therapies to market. His vision and leadership will be instrumental as the Jupiter team enters this next clinical phase. We are confident that, under Carl’s guidance, Jupiter Endovascular will address a significant clinical need that has remained unmet for decades.”
Source: Jupiter Endovascular
published: August 16, 2024 in: Cardio, Clinical Studies/Trials, Companies, Company News, News, Thoracic/Respiratory, Vascular
